Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2024-04-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于关联方向公司提供借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding related party transactions involving loans provided by the controlling shareholder and other related parties to the company. It details the terms, purpose, and approvals related to these loans. The content focuses on financing activities and capital structure changes, specifically related to borrowing arrangements with related parties. The document is not a full financial report, earnings release, or regulatory certification, but rather an update on capital/financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2536 characters, which is sufficient for a detailed announcement but not a full report.
2024-04-29 Chinese
关于2023年度核销坏账及计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Haier Bioengineering Co., Ltd. regarding the 2023 annual asset impairment provisions and bad debt write-offs. It details the amounts and reasons for asset impairment and bad debt provisions for the fiscal year ending December 31, 2023. The document includes specific financial figures and explanations of accounting policies applied, but it is not a full annual report or interim financial report. It is a regulatory announcement about impairment and bad debt provisions, which is typical for a Regulatory Filings (RNS) category. The document length is 3448 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full audit report or a management discussion and analysis report. Therefore, the best classification is Regulatory Filings (RNS).
2024-04-29 Chinese
2023年度独立董事述职报告（章卫东）
Board/Management Information Classification · 95% confidence The document is titled '2023 年度独立董事述职报告（章卫东）' which translates to '2023 Annual Independent Director's Work Report (Zhang Weidong)'. It is a detailed report by an independent director about his duties, attendance, and activities during the year 2023. The content includes descriptions of board meetings attended, committee work, internal control evaluations, financial report reviews, and governance matters. It is a comprehensive report on the independent director's role and oversight during the year, rather than an announcement or a brief summary. This type of document fits best under Board/Management Information (MANG) as it relates to management and board-level reporting on governance and director activities. It is not an annual report (10-K), audit report (AR), or a regulatory filing (RNS). The document length and detail confirm it is a full report, not a short announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-29 Chinese
2023年年度财务报告
Annual Report Classification · 100% confidence The document is titled as the "2023 Annual Report" of Shenzhen Haier Bioengineering Co., Ltd. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, audit report with unqualified opinion, auditor's responsibilities, management responsibilities, and detailed notes on key audit matters such as goodwill impairment, revenue recognition, and bad debt provisions. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of comprehensive financial data, audit opinions, and management discussion confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2023. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-29 Chinese
董事局关于2023年度内部控制审计报告带强调事项段的无保留审计意见涉及事项的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a report from the Board of Directors regarding the 2023 internal control audit report with an emphasis paragraph and an unqualified opinion. It discusses the internal control audit conducted by an accounting firm, mentions specific internal control deficiencies, and outlines corrective measures taken by the company. The content is focused on audit results and internal control issues rather than a full annual report or financial statements. The document is relatively short (1895 characters) and is a detailed explanation of the audit report and related matters, not a mere announcement or certification. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-29 Chinese
深圳市海王生物工程股份有限公司2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司2024 年第一季度报告" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis. It also mentions that the report is unaudited. The length of the document (12,255 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.